deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04718883

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma

Sponsor: Shanghai Ming Ju Biotechnology Co., Ltd.

Conditions Mantle Cell Lymphoma
Interventions CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Updated 5 times since 2021 Last updated: Nov 21, 2023 Started: Jan 13, 2021 Primary completion: Oct 25, 2023 Completion: Aug 7, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Mantle Cell Lymphoma and is currently ongoing. Shanghai Ming Ju Biotechnology Co., Ltd. leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Dec 2023 · 32 months · monthly snapshotRecruiting~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotActive Not Recruiting

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Apr 2021 — Dec 2023 [monthly]

    Recruiting PHASE2

  5. Feb 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Ming Ju Biotechnology Co., Ltd.
Data source: Shanghai Ming Ju Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations